Cresemba® and Zevtera®-related revenues rise by 24% to CHF 90.5 millionTotal revenue grows significantly by 36% to CHF 104.0 millionOperating profit surges by 160% to CHF 24.0 millionOperating cash flow increases by 29% to CHF 23.1 millionFull-year 2025 guidance: on track and updated to reflect recent in-licensing of a novel oral phase 3-ready antibiotic Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, August 19, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage bio ...

Cresemba® and Zevtera®-related revenues rise by 24% to CHF 90.5 millionTotal revenue grows significantly by 36% to CHF 104.0 millionOperating profit surges by 160% to CHF 24.0 millionOperating cash flow increases by 29% to CHF 23.1 millionFull-year 2025 guidance: on track and updated to reflect recent in-licensing of a novel oral phase 3-ready antibiotic Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, August 19, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage bio ...

Core Insights - Basilea Pharmaceutica Ltd has received an additional USD 39 million from BARDA to advance the development of its antifungal drugs fosmanogepix and BAL2062, following the successful completion of a milestone under the "Other Transaction Agreement" [1][2] - The total potential funding from BARDA could reach approximately USD 268 million over up to 12 years, contingent on the successful completion of predefined milestones [1][2] Funding and Development - The new funding of USD 39 million is in addition to the initial USD 29 million committed by BARDA at the signing of the OTA in September 2024 [2] - BARDA's financial contribution is expected to cover about 60% of the total costs for the supported projects [2] - The funding will support ongoing phase 3 studies for fosmanogepix in yeast infections and the initiation of a second phase 3 study for mold infections, as well as preparations for a phase 2 study for BAL2062 [2] Product Information - Fosmanogepix is a clinical-stage broad-spectrum antifungal with a novel mechanism of action, effective against common and multi-drug-resistant strains of Candida and Aspergillus [3] - BAL2062 is a first-in-class antifungal derived from a natural product, showing fungicidal activity against important molds, including azole-resistant strains [4] Market Need - There is a high medical need for new antifungals due to the increasing incidence of difficult-to-treat infections, particularly among immunocompromised patients [2][5] - Invasive candidiasis is a significant nosocomial infection, with Candida species being a leading cause of bloodstream infections in hospitals [7]